Navigation Links
Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
Date:5/13/2013

00 p.m. Pacific Time with management to discuss results from the meeting as well as financial results for the first quarter and provide a general corporate update.

About Anthera PharmaceuticalsAnthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases.  Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy, or IgAN, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2013.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., dlutz@anthera.com
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
2. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
3. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
5. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
6. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
7. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
8. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
9. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
11. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- The Galien Foundation today announced the 2014 nominees ... Awards. The Prix Galien Award is considered ... scientific and clinical research skills necessary to develop innovative ... highest number of nominees since the inception of the ... biomedical products across three categories – biotechnology, pharmaceutical, and ...
(Date:7/31/2014)... Cryoport, Inc. (OTCBB: CYRX) today announced financial results for ... Recent Operating Highlights , Achieved 92% ... period ended June 30, 2014 compared to the prior ... expand Cryoport,s global reach using the ,powered by Cryoport ... an immunotherapy and vaccine development services company, to support ...
(Date:7/31/2014)... , July 31, 2014  Genomic Health, Inc. (Nasdaq: ... a conference call and webcast on Thursday, August 7 at ... financial results.  The call and webcast will follow the release ... Conference Call Details To access the live conference call ... please dial (877) 303-7208 from the United States ...
Breaking Medicine Technology:The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 2The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 3The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 4The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 5Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 2Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 3Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 4Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 5Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 6Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 7Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 8Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 2Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 3Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 4
... Report Issued to Improve Policies Affecting How Human ... At the same time,that medical science is making ... once fatal diseases, a new report finds major,shortcomings ... out and,funded in the U.S. with serious implications ...
... Belgium, April 1 , - Trial Results Expected ... company,focused on vascular diseases, eye diseases and cancer, today ... IIb MIVI III trial in the,United States. This study ... in vitrectomy (MIVI III - Microplasmin for Vitreous,Injection)., ...
Cached Medicine Technology:Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation 2Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation 3Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation 4Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation 5Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation 6Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation 7ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III) 2ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III) 3ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III) 4
(Date:8/1/2014)... 2014 Stress management can be difficult in ... of concentration and diminish rest and leisure time, stress can ... critical to find a way to manage stress in order ... , “Having a good sense of work-life balance is the ... founding clinician of SF Custom Chiropractic. “Stress, left unchecked, ...
(Date:8/1/2014)... Register to join the webinar here: http://bit.ly/1lPZNI9 . ... record for life sciences investing. IPOs in the sector tripled ... all venture dollars spent in 2013. The result: biotech companies ... However, 2014 is proving more of a mixed bag of ... while life sciences IPOs are losing steam, M&A is expected ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Just in ... Duke’s Chowder House is featuring new summertime drink ... all six Duke’s locations throughout the season. ... guests alike, Duke’s award-winning, customer-nominated Seattle’s best happy hour ... To celebrate its Lake Union location’s 25th anniversary this ...
(Date:7/31/2014)... San Francisco, California (PRWEB) July 31, 2014 ... 1960s Grateful Dead Psychedelic Acid Test concert posters. Owsley ... bolt skull logo for the Grateful Dead. According to ... Ken Kesey to promote acid test parties in San ... test posters were printed on three different colors of ...
(Date:7/31/2014)... 2014) If you have asthma, you may have an ... you recognize and respond to changes and understand when symptoms ... the green zone, you,re doing well, yellow means your asthma ... require urgent care. New guidelines are now available to help ... into green and away from the red zone. , "Management ...
Breaking Medicine News(10 mins):Health News:SF Custom Chiropractic Celebrates National Relaxation Day and the Benefits of Massage Therapy for the Month of August 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 3Health News:Seattle Seafood Restaurant Lake Union Duke's Chowder House Celebrating its 25th Anniversary, Still a Best Outdoor Deck Spot to Sip Up Cocktails in Record-Breaking Heat. 2Health News:Seattle Seafood Restaurant Lake Union Duke's Chowder House Celebrating its 25th Anniversary, Still a Best Outdoor Deck Spot to Sip Up Cocktails in Record-Breaking Heat. 3
... effective, a new review of studies has found. Not ... depression and health-related quality of life, they also reduce ... analysis was both more inclusive and more conservative than ... that these interventions are helpful,” said psychologist and review ...
... last year, Soraya Kohanzadeh, 30, Muir Beach, CA, was ... and expecting to live a shortened life// dependent on ... her “anti-donor” antibody levels were so high, her doctors ... ever. However, thanks to a specialized type of anti-rejection ...
... Merck and Co., hopes to offer Gardasil, to developing countries ... the only vaccine against Human Papilloma Virus, that is insinuated ... Statistics reveal that cervical cancer is rampant in developing countries.80% ... in developing nations. ,A single dose of Gardasil ...
... method to identify deposits in brain seen in people ... this disorder suffer mostly in their cognitive abilities and ... be able to distinguish people who may develop Alzheimer's ... extent .Nearly 5 million people in the USA are ...
... Medicine have pinpointed a key regulatory protein that translates ... in a model of mouse embryonic development a transcription ... blood vessels, is activated by rapid, pulsed blood flow, ... Understanding Klf2’s role in blood vessel and muscle biology ...
... their collaborators are gaining widespread attention for discoveries involving ... to AIDS patients. Their findings about Toxoplasma gondii and ... Nature published a paper Wednesday, Dec. 20, in its ... 15 and PLoS Pathogens on Oct. 27. ...
Cached Medicine News:Health News:Psychological Treatments Improve Outcomes for Back Pain Sufferers 2Health News:Psychological Treatments Improve Outcomes for Back Pain Sufferers 3Health News:Therapy Modulates Highly Sensitized Immune System to Let Mother Give Kidney to Daughter 2Health News:Therapy Modulates Highly Sensitized Immune System to Let Mother Give Kidney to Daughter 3Health News:Therapy Modulates Highly Sensitized Immune System to Let Mother Give Kidney to Daughter 4Health News:Novel Brain Scan to Diagnose Alzheimer's Disease 2Health News:Novel Brain Scan to Diagnose Alzheimer's Disease 3Health News:How Blood Flow Dictates Gene Expression 2Health News:New Findings on Toxoplasmosis 2Health News:New Findings on Toxoplasmosis 3
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
... Inverness Medical Professional Diagnostics is a leading ... IFA and DFA test menu that includes ... STDs as well as miscellaneous conjugates and ... you a wide assortment of substrates and ...
Medicine Products: